Samra Turajlić, Group Leader at Cancer Research UK Manchester Institute, shared Max Emmerich’s post on LinkedIn, adding:
“We are very proud of our colleague Max Emmerich who was a recipient of two early investigators awards by Society for Immunotherapy of Cancer (SITC) at SITC2026 in Phoenix.
Max is a brilliant ambassador for MANIFEST IO Platform and Consortium, leading on our efforts to better understand, prevent and treat immune-related adverse events associated with cancer immunotherapy.
This field gets more critical by the day and we are determined to make progress working with our NHS, Academic and Industry partners.”
Max Emmerich, Clinical Postdoctoral Fellow at The Francis Crick Institute, shared:
“Thank you Society for Immunotherapy of Cancer (SITC) for the opportunity to present our work on immune related adverse event biology across blood and tissue as two oral abstracts, each recognised with an early career investigator award at SITC2026 in beautiful Phoenix.
It was great to link up with so many irAE enthusiasts in the field and see the launch of the new Alliance for the Support and Prevention of Immune Related Adverse Events (ASPIRE) special interest group.
Our mission at MANIFEST IO, led by my mentor Samra Turajlić, is to improve ICI outcomes so that more patients can benefit from therapy whilst potentially devastating side effects are curbed.
We are fortunate to have fantastic hospital partners at The Royal Marsden NHS Foundation Trust, The Christie NHS Foundation Trust, a stellar team of scientists across The Francis Crick Institute, Cancer Research UK Manchester Institute, many other UK sites, and industry partners Nomic Bio and IMU Biosciences to tackle this task.”
You can also read:
Samik Upadhaya Shares Key Takeaways from SITC 2026 in Phoenix
